[ad_1]
As Japanese conglomerate Fujifilm continues to invest heavily in its CDMO sector, one of its manufacturing divisions is starting to invest heavily.
Fujifilm Irvine Scientific announced Tuesday that parent company Fujifilm is investing $188 million to build a cell culture media manufacturing facility at Research Triangle Park in North Carolina. The new site will be Fujifilm Irvine’s fifth manufacturing site in the world and his second manufacturing site in the United States.
The 250,000 square foot site is located on 64 acres within the research park and will produce dry powders and liquid media with a capacity of 800,000 kilograms of dry powder and 3.3 million liters of liquid media per year. The site also has a water for injection capacity of 40,000 liters per day.
Both land development and construction are expected to begin in 2023, with production beginning in 2025. The company also plans to employ about 100 workers on site.
“Cell culture media manufactured at this new North Carolina facility will help ensure a stable supply of raw materials for biologics, cell and gene therapies, and other key pharmaceutical products essential to human health. The additional production capacity will ensure we can meet the anticipated demand for cell culture media from our customers around the world,” said Yutaka Yamaguchi, CEO of FUJIFILM Irvine Scientific, in a statement.
Fujifilm Irvine is building a second U.S. site due to projected “rapid growth” over the past decade and increased demand for cell culture media to support more “advanced therapies.” increase. Research Triangle Park was chosen because it is the “ideal location” for securing the supply chain and serving as a starting point to reach local customers.
Fujifilm enters the very hot area of broader biotechnology and pharmaceutical manufacturing. Companies like KBI, Chinese cell therapy company CARsgen and Enzyvant have all raised the flag in the last few years and set up manufacturing operations in the park.
Last year, Eli Lilly announced the addition of an eighth site to its network of manufacturing plants in the United States, investing $470 million to begin production of injectable products and delivery devices at Research Triangle Park.
Fujifilm’s CDMO, Fujifilm Diosynth, is working on several projects in the region and last year expanded its Bioprocess Innovation Center in Research Triangle Park, replacing an existing laboratory in Thar Kheer province. Announced doubling the footprint and adding another 145. By 2024 he will bring 89,000 square feet of jobs to the site.
Last October, Fujifilm Diosynth broke ground on a $2 billion project at a site to manufacture active pharmaceutical ingredient cell cultures in nearby Holly Springs, North Carolina. The site has eight he 20,000 liter bioreactors, with the potential to add another 24 in the future based on market demand.
[ad_2]
Source link